Intravenous Semelil (ANGIPARS™) as a novel therapy for pressure ulcers: A randomized clinical trial

Daru

Volumn 16, Issue SUPPL. 1, 2008, Pages 49-53

  Shamimi Nouri, K ^a   Heshmat, R ^b,c   Karimian, R ^a   Nasli, E ^b   Larijani, B ^b   Novitsky, Y A ^d   Farhadi, M ^e   Gharibdoust, F ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d European Asian Nano molecular Technology Center   (Russian Federation)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Intervention; Intravenous; Pressure ulcer; Semelil (ANGIPARS )

Indexed keywords

ANGIPARS; HERBACEOUS AGENT; SEMELIL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECUBITUS; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOOT ULCER; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; ULCER HEALING;

EID: 38949141576     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Berlowitz DR, Bezerra HQ, Brandeis GH, Kader B, Anderson JJ. Are we improving the quality of nursing home care: the case of pressure ulcers. J Am Geriatr Soc. 2000;48:59-62.
2. Smith DM. Pressure ulcers in the nursing home. Ann Intern Med. 1995;123: 433-42.
3. Mukamel DB, Spector WD. Nursing home costs and risk-adjusted outcome measures of quality. Med Care. 2000;38:78-89.
4. Hollisaz MT, Khedmat H, Yari F. A randomized clinical trial comparing hydrocolloid, phenytoin and simple dressings for the treatment of pressure ulcers. BMC Dermatol. 2004; 4: 18
5. Baxter CR. Immunologic reactions in chronic wounds. Am J Surg 1994; 167:12S-14S.
6. Berlowitz DR, Wilking SVB. The short-term outcome of pressure sores. J Am Geriatr Soc 1990; 38:748-752.
7. Larijani B, Hasani Ranjbar S. Overview of diabetic foot; novel treatments in diabetic foot ulcer. DARU 2008; 16(suppl.1): 1-6.
8. Abdollahi M, Farzamfar B, Salary P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Rodent acute and sub-chronic toxicity evaluation of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing. DARU 2008; 16(suppl.1): 7-14.
9. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky Y.A, Farhadi M. Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. DARU 2008; 16(suppl.1): 15-19.
10. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salary P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™). DARU 2008; 16(suppl.1): 20-24.
11. Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial. DARU 2008; 16(suppl.1): 25-30.
12. Masoompour SM, Bagheri MH, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer : A phase 2 clinical study. DARU 2008; 16(suppl.1): 31-34.
13. Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K, Heidarpour R, Mohajeri Tehrani MR, Kamali K, Farhadi M, Gharibdoust F, Madani SH. Effects of Intravenous Semelil (ANGIPARSTM) on Diabetic Foot Ulcers Healing: A Multicenter Clinical Trial. DARU 2008; 16(suppl.1): 35-40.
14. Thomas D. Existing tools: Are they meeting the challenges of pressure ulcer healing? Adv Wound Care 1997; 10:86-90
15. Reed JW. Pressure ulcers in the elderly: prevention and treatment utilizing the team approach. MD State Med J 1981; 30:45-50.
16. Guralnik JM, Harris TB, White LR, et al. Occurrence and predictors of pressure ulcers in the National Health and Nutrition Examination Survey Follow-up. J Am Geriatr Soc 1988; 36:807-812
17. Lawrence WT, Diegelmann RF. Growth factors in wound healing. Clin Dermatol 1994; 12:157-169.
18. Robson MC, Phillips LG, Thomason A, et al. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg 1992; 29:193-201.
19. Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339:23-25.
20. Robson MC, Phillips LG, Lawrence WT, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992; 216:401-408.
21. Waldorf H, Fewkes J. Wound healing. Adv Dermatol. 1995;10:77-96.
22. Waldorf H, Fewkes J. Wound healing. Adv Dermatol. 1995;10:77-96.
23. Rothe MJ, Falanga V. Growth factors and wound healing. Clin Dermatol. 1991;9:553-9.
24. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83:835-70.
25. Higashiyama M, Hashimoto K, Takada A, Fujita K, Kido K, Yoshikawa K. The role of growth factor in wound healing. J Dermatol. 1992;19:676-9.
26. Bahrami A, Kamali K, Ali-Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorram HR, Gharibdoust F, Madani SH, Larijani B. Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial. DARU 2008; 16(suppl.1): 41-48.